Antipsychotic News and Research RSS Feed - Antipsychotic News and Research

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
Antipsychotic polypharmacy prevalent despite efficacy doubts

Antipsychotic polypharmacy prevalent despite efficacy doubts

Results of a retrospective study suggest that around a quarter of patients with schizophrenia receive antipsychotic polypharmacy, despite a lack of evidence for the approach. [More]
Novel drug target could lead to better antipsychotic medications

Novel drug target could lead to better antipsychotic medications

Scientists at the Centre for Addiction and Mental Health have identified a novel drug target that could lead to the development of better antipsychotic medications. [More]
Excess mortality in schizophrenia ‘not attributable to antipsychotics’

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

The relationship between antipsychotic use and mortality in people with schizophrenia shows a clear U-shape curve, with the highest risk of death seen in those with no antipsychotic exposure, a Swedish cohort study has found. [More]
People with first-episode psychosis may benefit from medication treatment changes, study finds

People with first-episode psychosis may benefit from medication treatment changes, study finds

Many patients with first-episode psychosis receive medications that do not comply with recommended guidelines for first-episode treatment, researchers have found. Current guidelines emphasize low doses of antipsychotic drugs and strategies for minimizing the side effects that might contribute to patients stopping their medication. [More]
Lewy body dementia: 10 things people need to know

Lewy body dementia: 10 things people need to know

The recent news that the brain of actor/comedian Robin Williams showed signs of diffuse Lewy body disease has created more interest and coverage in this widely under-diagnosed condition than ever before. [More]
Successful antipsychotic treatment may alter striatal connectivity

Successful antipsychotic treatment may alter striatal connectivity

Connectivity within the striatum changes as psychotic symptoms improve in patients treated with second-generation antipsychotics, a study shows. [More]
Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. [More]

Schizophrenia symptom severity predicts atypical antipsychotic benefit

Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry. [More]
Metabolic syndrome screening in bipolar disorder warranted

Metabolic syndrome screening in bipolar disorder warranted

The frequency of the metabolic syndrome in patients with bipolar disorder warrants systematic screening, say researchers, particularly among men, older patients and those receiving atypical antipsychotic treatment. [More]
Physical health management below par in schizophrenia patients

Physical health management below par in schizophrenia patients

The diagnosis and treatment of physical ailments in patients with schizophrenia falls below acceptable standards, shows a national audit of patients in England and Wales. [More]
Study finds that mental health disorders double heart disease, stroke risks

Study finds that mental health disorders double heart disease, stroke risks

People facing mental health challenges are significantly more likely to have heart disease or stroke, according to a study presented today at the Canadian Cardiovascular Congress. [More]
Insulin resistance linked to treatment-refractory bipolar disorder

Insulin resistance linked to treatment-refractory bipolar disorder

Patients with bipolar disorder who are insulin resistant are likely to also be refractory to mood-stabilising treatment, report researchers. [More]

Changing placebo response dilutes antipsychotic trial power

Factors including patients’ expectations may underlie an increased placebo response in antipsychotic randomised controlled trials published since 1960, say researchers. [More]
Aspirin can improve efficacy of schizophrenia treatments

Aspirin can improve efficacy of schizophrenia treatments

A new study shows that some anti-inflammatory medicines, such as aspirin, estrogen, and Fluimucil, can improve the efficacy of existing schizophrenia treatments. This work is being presented at the European College of Neuropsychopharmacology conference in Berlin. [More]
New drug naming system to be presented at ECNP conference in Berlin

New drug naming system to be presented at ECNP conference in Berlin

What's in a name? Doctors have found that the name of the drug you are prescribed significantly influences how the patient sees the treatment. [More]
Cardiometabolic health intervention urged for schizophrenia patients

Cardiometabolic health intervention urged for schizophrenia patients

Research shows high cardiometabolic risk, particularly increased dyslipidaemia and smoking, but little related medical treatment in patients with first-episode schizophrenia. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]
State highlights: Md., Minn. see small business health insurance rate changes; Texas sues AstraZeneca over Seroquel marketing

State highlights: Md., Minn. see small business health insurance rate changes; Texas sues AstraZeneca over Seroquel marketing

Some small businesses in Maryland will see a small drop in health insurance premiums next year, while others will pay as much as 11 percent more to cover their workers, according to rates released by state regulators Friday. The rates, which go into effect in January, only apply to small firms with up to 50 employees, and not to large or self-insured firms or individuals buying coverage on the state's health insurance exchange. Evergreen Health Cooperative sought no rate increase, and Aetna Health Inc. will raise rates only slightly, according to the rate information released by the Maryland Insurance Administration. Some UnitedHealthcare premiums will drop by about 2.5 percent (Cohn, 10/10). [More]
Pointers for boosting prophylactic bipolar treatment reported

Pointers for boosting prophylactic bipolar treatment reported

Patients with newly diagnosed bipolar disorder who have not previously used psychiatric drugs or have short hospital admissions should be targeted for prophylactic treatment, say researchers. [More]
Complex associations underlie functional variance in schizophrenia

Complex associations underlie functional variance in schizophrenia

The complex associations between predictors and mediators of real-life functioning highlight the need for integrated and personalised treatment for patients with schizophrenia, say researchers in World Psychiatry. [More]